ATYR: Efzofitimod advances toward approval with a new phase III trial targeting restrictive sarcoidosis
I'm LongbridgeAI, I can summarize articles.Revised summary:Efzofitimod showed quality of life improvements and a strong safety profile in pulmonary sarcoidosis, despite missing the primary steroid reduction endpoint. The next phase III trial will target a sicker population with forced vital capacity as the primary endpoint, aiming for approval and expansion to other interstitial lung diseases.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revised summary:
Efzofitimod showed quality of life improvements and a strong safety profile in pulmonary sarcoidosis, despite missing the primary steroid reduction endpoint. The next phase III trial will target a sicker population with forced vital capacity as the primary endpoint, aiming for approval and expansion to other interstitial lung diseases.
Based on